General Principles - The financial management system of Shandong Weiming Biological Pharmaceutical Co., Ltd. aims to standardize accounting recognition, measurement, and reporting to ensure the quality of accounting information and improve economic efficiency while protecting shareholders' rights [1][2][3] Financial Management Structure and Personnel - The company has established a financial management organization under the leadership of the board of directors, with the general manager responsible for implementation [2][3] - A planning finance center is set up to handle financial management and accounting matters, staffed with qualified accounting personnel [2][3] - The company has the authority to appoint and dismiss financial heads of its subsidiaries, while other financial personnel are hired according to internal regulations [2][3] Accounting Policies and Estimates - The company adopts a calendar year as its accounting period, running from January 1 to December 31 [3][4] - The functional currency for accounting is determined based on the primary economic environment, with RMB used for companies established in mainland China [4][5] - The company uses the accrual basis of accounting and historical cost for measurement [4][5] Financial Asset Recognition and Measurement - Financial assets are classified at initial recognition into categories such as amortized cost, fair value through other comprehensive income, and fair value through profit or loss [5][6] - The company assesses credit risk and recognizes impairment losses based on expected credit losses [8] Inventory Accounting - Inventory is initially measured at cost and includes raw materials, finished goods, work in progress, and low-value consumables [9] - The company uses the weighted average method for inventory issuance and recognizes impairment when the cost exceeds the net realizable value [9] Long-term Equity Investment Accounting - The company uses the cost method for subsequent measurement of long-term equity investments in subsidiaries and adjusts for equity method in consolidated financial statements [10] Fixed Assets and Depreciation - Fixed assets are recorded at actual cost and depreciated using the average annual method based on asset categories [11][12] Intangible Assets Accounting - Intangible assets are initially measured at cost, including purchase price and related expenses, and are amortized over their useful lives [13][14] Revenue Recognition - Revenue is recognized when control of the goods is transferred to the customer, and specific criteria must be met [21] Tax Accounting - The company uses the balance sheet liability method for income tax accounting, recognizing deferred tax assets or liabilities based on differences between the book value and tax base of assets and liabilities [17] Financial Reporting - The company prepares financial reports including balance sheets, income statements, cash flow statements, and changes in equity statements, adhering to relevant accounting standards [23][24][25]

General Principles - The purpose of the management system is to strengthen control over subsidiaries, standardize internal operations, protect the rights of the company and investors, and promote healthy development of subsidiaries [1][2] - The company maintains a relationship of equal legal status with its subsidiaries, exercising shareholder rights and providing guidance and supervision [2][3] - The system aims to enhance risk control, improve operational efficiency, and increase the company's overall risk resistance [2][3] Personnel Management - The company, as the main investor, exercises shareholder rights through the subsidiary's shareholders' meeting and appoints representatives and management [4][5] - Personnel appointed by the company must adhere to legal obligations and cannot exploit their positions for personal gain [5][6] - Training is provided to subsidiary management to ensure compliance with relevant laws and company regulations [5][6] Financial Management - Subsidiaries must comply with national fiscal and tax policies and establish their own financial management systems [7][8] - The company supervises the financial management of subsidiaries and requires timely reporting of financial statements [8][9] - Subsidiaries must adhere to the company's accounting policies and ensure the legality and accuracy of financial data [8][9] Operational Decision-Making - Subsidiaries must align their operational plans with the company's overall strategy and adhere to legal regulations [10][11] - Major transactions exceeding the subsidiary's authority require approval from the company's management [10][11] - Subsidiaries are responsible for conducting due diligence and feasibility studies before making investment decisions [11][12] Information Disclosure - Subsidiaries must follow the company's information disclosure policies and report significant matters promptly [12][13] - Meetings held by subsidiaries must be reported to the company for approval and documentation [13][14] - The company requires accurate and timely reporting of operational and financial information from subsidiaries [14][15] Internal Audit and Supervision - The company conducts regular audits of subsidiaries to ensure compliance with laws and internal regulations [15][16] - Subsidiaries must cooperate with audits and implement corrective measures for identified issues [15][16] - The internal audit system of the company applies to subsidiaries, ensuring accountability and transparency [16][17] Assessment and Rewards - Subsidiaries are required to establish their own assessment and reward systems based on the company's guidelines [17][18] - Annual assessments of senior management are conducted based on performance metrics and audit results [17][18] - The company reserves the right to impose penalties on subsidiary management for failing to fulfill their responsibilities [18]

Core Viewpoint - The internal control system of Shandong Weiming Biological Pharmaceutical Co., Ltd. aims to enhance corporate governance, ensure compliance, protect investor rights, and promote sustainable development through a structured framework [1][2]. Group 1: General Principles - The internal control system is designed to ensure legal compliance, asset security, and the authenticity of financial reporting [1]. - The board of directors is responsible for the establishment, implementation, and improvement of the internal control system, with regular evaluations of its effectiveness [1][2]. Group 2: Basic Requirements - Internal control should consider elements such as internal environment, risk assessment, control activities, information communication, and internal supervision [2]. - The company must establish a governance structure that promotes effective decision-making and risk awareness [3]. Group 3: Control Activities - Internal control activities must cover all business segments related to financial reporting and information disclosure, including sales, procurement, inventory, and asset management [3]. - The company must ensure that its assets are independently owned and not misappropriated by controlling shareholders or related parties [4]. Group 4: Risk Management - A comprehensive risk assessment system should be established to monitor various risks, including operational, financial, market, regulatory, and ethical risks [5]. - The company should implement a robust internal audit function to evaluate the effectiveness of internal controls and report findings to the board [6][16]. Group 5: Subsidiary Management - The company must develop control policies for subsidiaries, ensuring they establish their own internal control systems based on their business characteristics [6]. - Regular performance evaluations and financial reporting from subsidiaries are required to maintain oversight [6]. Group 6: Related Party Transactions - Internal controls for related party transactions must adhere to principles of honesty, equality, and fairness, ensuring no harm to the company or its shareholders [7]. - The company must establish clear approval processes for related party transactions, including the requirement for independent directors to review such matters [8]. Group 7: External Guarantees and Fund Management - The company must manage external guarantees with a focus on legality, prudence, and mutual benefit, ensuring risks are controlled [9]. - A management framework for the use of raised funds must be established, ensuring compliance with stated purposes and effective tracking of fund usage [12][13]. Group 8: Major Investments and Information Disclosure - Major investments should be subject to rigorous evaluation and approval processes to mitigate risks and ensure effective returns [14]. - The company must maintain a robust information disclosure system to report significant events that could impact stock prices [15]. Group 9: Internal Audit and Evaluation - The internal audit department is responsible for assessing the completeness and effectiveness of internal controls across the company and its subsidiaries [16]. - Regular internal control evaluations should be conducted, with findings reported to the board for necessary actions [17][18].

General Overview - The document outlines the working rules of the Audit Committee of Shandong Weiming Biological Pharmaceutical Co., Ltd, aiming to enhance the decision-making capacity of the board and ensure effective supervision of the management [1][2]. Composition of the Audit Committee - The Audit Committee consists of three directors, including two independent directors, with an accounting professional serving as the chairperson [2]. - The committee members are nominated by the chairman or a majority of independent directors and elected by the board [2]. - The term of the Audit Committee aligns with that of the board, and members can be re-elected [2]. Responsibilities and Authority - The main responsibilities of the Audit Committee include supervising external and internal audits, reviewing financial reports, and assessing internal controls [4][5]. - The committee must approve certain actions, such as the disclosure of financial reports and the hiring or firing of external auditors, before submission to the board [10][11]. - The committee is tasked with guiding and supervising the internal audit department and ensuring compliance with laws and regulations [12]. Meeting Procedures - The Audit Committee is required to hold at least one regular meeting each quarter, with provisions for special meetings as needed [22][23]. - Meeting notifications must include the date, location, agenda, and other relevant details [24]. - A quorum for meetings requires the presence of at least two-thirds of the committee members, and decisions are made by a majority vote [26][27]. Documentation and Reporting - Meeting minutes must be recorded, detailing attendance, agenda items, and voting results, and these records are to be maintained for a minimum of ten years [33][36]. - The committee is responsible for reporting its activities and any significant issues to the board, ensuring transparency and accountability [20][21].

Core Viewpoint - The document outlines the fundraising management system of Shandong Weiming Biological Pharmaceutical Co., Ltd, emphasizing the proper storage, usage, and management of raised funds to enhance efficiency and protect investors' rights [1][2]. Group 1: Fundraising Management Principles - The company must establish a detailed plan for the use of raised funds, ensuring transparency and compliance with national laws and regulations [2][4]. - The board of directors is responsible for the effective implementation of the fundraising management system [1][2]. - Funds raised must be stored in a dedicated account and cannot be used for non-designated purposes [7][8]. Group 2: Fund Usage Regulations - Raised funds should be used strictly for the purposes disclosed in the prospectus or other public documents, and any changes must be approved by the shareholders [9][11]. - The company is prohibited from using raised funds for high-risk investments or providing financial assistance to others [11][12]. - Any changes in the investment projects must undergo a feasibility analysis and be disclosed promptly [14][15]. Group 3: Oversight and Reporting - The company must maintain detailed records of the usage of raised funds and undergo regular audits to ensure compliance [33][34]. - The board must report on the status of fundraising and usage at least semi-annually, including any discrepancies in investment progress [15][16]. - Independent financial advisors or sponsors are required to conduct regular checks and report any irregularities [17][18].

山东未名生物医药股份有限公司董事会 提名委员会工作细则 （经2025年7月30日召开的第六届董事会第四次会议审议通过） 第一章 总则 第一条 为规范山东未名生物医药股份有限公司（下称公司）董事及高级管 理人员的选聘，优化董事会成员组成，完善公司治理结构，根据《中华人民共 和国公司法》（以下简称《公司法》）、《上市公司治理准则》和《深圳证券 交易所上市公司自律监管指引第1号—主板上市公司规范运作》等法律、行政法 规、部门规章、规范性文件及《山东未名生物医药股份有限公司章程》（以下 简称《公司章程》）的规定，结合公司实际情况，设立董事会提名委员会（以 下简称提名委员会），并制定本细则。 第二条 提名委员会是董事会设立的专门工作机构，对董事会负责，依照 《公司章程》和董事会的授权履行职责。提名委员会主要负责对公司董事和高 级管理人员的人选、选择标准和程序进行选择并提出建议。 第七条 提名委员会任期与董事会任期一致，委员任期届满，连选可以连 任。 委员任期届满前，除非出现《公司法》《公司章程》或本细则规定的不得 任职之情形，不得被无故解除职务。期间如有委员不再担任公司董事职务，自 动失去委员资格，董事会根据本细则的规 ...

及其变动管理制度 （经 2025 年 7 月 30 日召开的第六届董事会第四次会议审议通过） 董事和高级管理人员所持公司股份 第一章 总则 山东未名生物医药股份有限公司 第一条 为加强对山东未名生物医药股份有限公司（以下简称公司或本公司） 董事和高级管理人员所持本公司股份及其变动的管理，进一步明确办理程序，根 据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券 法》（以下简称《证券法》）、《上市公司董事和高级管理人员所持本公司股份 及其变动管理规则》、《上市公司股东减持股份管理暂行办法》、《深圳证券交 易所上市公司自律监管指引第 18 号——股东及董事、高级管理人员减持股份》 （以下简称《监管指引第 18 号》）、《深圳证券交易所股票上市规则》（以下 简称《股票上市规则》）、《深圳证券交易所上市公司自律监管指引第 1 号—— 主板上市公司规范运作》、《深圳证券交易所上市公司自律监管指引第 10 号— —股份变动管理》等法律、行政法规、部门规章、规范性文件以及《山东未名生 物医药股份有限公司章程》（以下简称《公司章程》）的有关规定，结合公司实 际情况，制定本制度。 第二条 本制度适用于公司董 ...

山东未名生物医药股份有限公司 对外投资管理办法 （经2025年7月30日召开的第六届董事会第四次会议审议通过） 第一章 总则 第一条 为了加强山东未名生物医药股份有限公司（以下简称公司）对外投 资的内部控制和管理，规范公司对外投资行为，提高资金运作效率，保障公司 对外投资保值、增值，根据《中华人民共和国公司法》（以下简称《公司 法》）、《中华人民共和国证券法》《深圳证券交易所股票上市规则》（以下 简称《上市规则》）、《深圳证券交易所上市公司自律监管指引第 1 号——主 板上市公司规范运作》等法律、行政法规、部门规章和规范性文件及《山东未 名生物医药股份有限公司章程》（以下简称《公司章程》）的规定，结合公司 实际情况，特制定本办法。 第二条 本办法所称的对外投资，是指公司以货币资金、股权、技术、债权、 厂房、设备、土地使用权等实物或无形资产作价出资等形式对境内外其他法人 实体或经济组织的长期投资，包括发起投资、追加投资、收购兼并和共同投资 合作项目等。不包括金融投资（含证券投资、期货投资、委托理财、债券投资、 基金投资及以股票、利率、汇率和商品为基础的期货、期权、权证等衍生产品 投资等）。 第三条 本制度适用公 ...

山东未名生物医药股份有限公司 关联交易决策制度 （经2025年7月30日召开的第六届董事会第四次会议审议通过） 第一章 总则 第一条 为规范山东未名生物医药股份有限公司（以下简称公司）的关联 交易，保护公司、股东和债权人的合法权益，保证公司关联交易决策行为的公 允性，根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民 共和国证券法》（以下简称《证券法》）、《深圳证券交易所股票上市规则》 （以下简称《上市规则》）、《深圳证券交易所上市公司自律监管指引第1号— —主板上市公司规范运作》《深圳证券交易所上市公司自律监管指引第7号—— 交易与关联交易》等法律、行政法规、部门规章和规范性文件以及《山东未名 生物医药股份有限公司章程》（以下简称《公司章程》）的规定，结合公司实 际情况，特制定本制度。 第二条 在本制度中，关联交易是指公司或公司控股子公司与公司关联人 之间发生的转移资源或义务的事项。 （二）由前项所述法人（或者其他组织）直接或间接控制的除公司及其控股 子公司以外的法人（或者其他组织）； 公司关联人包括关联法人和关联自然人。 第三条 具有以下情形之一的法人或者其他组织，为公司的关联法人： （一）直 ...

山东未名生物医药股份有限公司 独立董事工作细则 （2025 年 7 月） 第一章 总则 第一条 为进一步完善山东未名生物医药股份有限公司（以下简称公司）的 法人治理结构，明确独立董事的工作职责，充分发挥独立董事的作用，维护公司 整体利益，保护广大投资者的利益，促进公司的规范运作，根据《中华人民共和 国公司法》（以下简称《公司法》）、《上市公司独立董事管理办法》（以下简 称《管理办法》）、《深圳证券交易所股票上市规则》（以下简称《股票上市规 则》）、《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范 运作》等法律、行政法规、部门规章、规范性文件及《山东未名生物医药股份有 限公司章程》（以下简称《公司章程》）的规定，结合公司实际情况，制定本工 作细则（以下简称本细则）。 第二章 独立董事的任职条件 第七条 公司独立董事候选人应当符合以下基本条件： （一）根据法律、行政法规和其他有关规定，具备担任上市公司董事的资格； （二）符合《公司章程》及本细则规定的独立性要求； 第二条 独立董事是指不在公司担任除董事外的其他职务，并与公司及主要 股东、实际控制人不存在直接或间接利害关系，或者其他可能影响其进行独 ...